Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Amphastar Pharmaceuticals, Inc.
Bear Case (25th pct.)
19.4% vs price
Base Case (Median)
43.5% vs price
Bull Case (75th pct.)
124.0% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $61.00 | 127.9% | High (40%) |
| PE Comparable | $38.41 | 43.5% | Medium (25%) |
| Growth Trajectory DCF | $75.38 | 181.6% | Medium (20%) |
| Graham Number | $26.22 | -2.1% | Medium (40%) |
| EV/EBITDA | $37.51 | 40.1% | Medium (20%) |
| EV/FCF | $58.93 | 120.1% | Medium (20%) |
| Earnings Power Value | $26.38 | -1.4% | Medium (50%) |
Based on 7 out of 7 methods, AMPH appears undervalued at the current price of $26.77. The base case fair value of $38.41 implies 43.5% upside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.